Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
Focus
2013:79:6;842-846
doi: 10.4103/0378-6323.120752
PMID: 24177629

# Systemic skin whitening/lightening agents: What is the evidence?

Munisamy Malathi, Devinder M Thappa
Department of Dermatology and STD, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India

Devinder M Thappa
Department of Dermatology and STD, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry - 605 006
India
 How to cite this article: Malathi M, Thappa DM. Systemic skin whitening/lightening agents: What is the evidence?. Indian J Dermatol Venereol Leprol 2013;79:842-846
Copyright: (C)2013 Indian Journal of Dermatology, Venereology, and Leprology

Introduction

The human skin color is one of the most perceptible phenotypic variations among humans and is determined primarily by the type and amount of melanin synthesized within melanosomes and the pattern of melanosome distribution within the melanocytes. Getting a lighter skin tone always draws a lot of interest, as for centuries, fair or light skin color has been a symbol of prominence, superiority and higher social ranking. In India, attitudes towards skin color have developed over more than 2000 years and reflect considerations of class and caste. Women especially Asian women are obsessed with fair skin and they would go to the ends of the earth to lighten their skin color as in most cases their marriage prospects or career opportunities are dominated by the hue of their skin. Hence, skin whitening products are a half a billion dollar industry today capitalizing on the insecurity of these individuals and currently, skin lightening is one of the most common forms of potentially harmful body modification practices in the world.

A host of skin lightening agents are available in dermatology and cosmetic market and newer agents are continuing to be introduced. A lot is known about topical skin whitening agents, but systemic skin whitening agents which are slowly gaining popularity do not have much evidence to their credit in the scientific literature. In this article, we have addressed the issues related to the use of these systemic skin whitening agents.

An overview of the pathway of melanin synthesis and the site of action of the most commonly used systemic skin whitening agent (glutathione [GSH]) is depicted in [Figure - 1]. The mechanisms governing pheomelanin to eumelanin balance are dependent on L-cysteine, GSH and tyrosinase related protein expression. Thus, as observed in the figure, the switching from eumelanogenesis to pheomelanogenesis can be influenced by modifying the ratio between cysteine and GSH levels. Pheomelanogenesis preferentially proceeds under conditions of high cysteine concentrations and low tyrosinase activity. [1]

 Figure 1: The pathway of melanin synthesis and the site of action of glutathione and cysteine, shifting the balance towards pheomelanin synthesis

Systemic Skin Whitening Agents Available in the Market

GSH

The most commonly used systemic skin whitening agent is GSH used alone or in various combinations, both as oral and intravenous formulations. GSH is an antioxidant synthesized in all mammalian cells from three amino acids-glutamate, cysteine, and glycine. It is also available naturally in watermelon, avocado, broccoli, spinach and tomatoes. GSH exists in cells mostly in the reduced form (GSH) which is constantly oxidized forming oxidized GSH and its supply is replenished by the action of GSH reductase. GSH is involved in various biochemical processes especially those involving scavenging of free radicals and detoxification of toxic compounds, it acts as coenzyme and helps in the transport of amino acids across the cell membranes. [1] Lower GSH levels are implicated in many diseases and GSH has been tried in the management of Alzheimer′s disease, Parkinson′s disease, multiple sclerosis, alcoholic hepatitis, atherosclerosis, acquired immunodeficiency syndrome, and chronic fatigue syndrome. It has been commonly used to combat the neuro- and nephrotoxicity associated with cisplatin chemotherapy [2] and this is the only Food and Drug Administration (FDA) approved indication for the intravenous form of GSH. The role of GSH as a skin whitening agent was an accidental discovery when skin whitening was noticed as a side effect of large doses of GSH. This led to extensive studies establishing its role in melanogenesis and the recent use of GSH as systemic skin whitening agent.

GSH exerts its action as skin whitening agent at various levels of melanogenesis which include the following: [1],[3]

• Interference with cellular transport of tyrosinase
• Direct inactivation of the enzyme tyrosinase by binding with the copper-containing active site of the enzyme
• Mediating the switch mechanism from eumelanin to phaeomelanin production as GSH is the major physiologic reservoir of cysteine and increase in cysteine levels results in switching of eumelanogenesis to pheomelanogenesis [Figure - 1]
• Quenching of free radicals and peroxides that contribute to tyrosinase activation and melanin formation
• Modulation of depigmenting abilities of melanocytotoxic agents.
GSH for skin whitening is available in both tablet and injectable form. When taken orally, GSH is hydrolyzed by intestinal and hepatic gamma-glutamyl transferase resulting in reduced bioavailability. Even when large oral doses were administered, it was found that most of the absorbed GSH remains within the gut luminal cells and only small and transient increases of GSH could be detected in the general circulation. [4] Thus, the effectiveness of exogenously administered GSH is hindered by its instability when crossing cell membranes and its rapid hydrolysis in the circulation by gamma-glutamyltranspeptidase found on the extracellular surfaces of cells. [5] On the contrary, intravenous GSH delivers very high doses directly into the systemic circulation, overloading the renal circulation.

Oral GSH is in the "generally regarded as safe" category of FDA and is usually marketed as a food or dietary supplement and hence it does not certainly need to be FDA or Bureau of Food and Drug (BFAD) approved. There are no provisions in the law for FDA to approve dietary supplements for effectiveness before they reach the consumer. However, FDA has banned the use of intravenous form of GSH for skin whitening in view of commonly reported side effects like skin rashes, Stevens Johnson syndrome, toxic epidermal necrolysis, derangement in thyroid and renal function and severe abdominal pain. [6]

Till date there is only one study published in English literature assessing the safety and efficacy of oral GSH as a skin whitening agent. [3] It was a randomized, double-blind, two-arm, placebo-controlled study conducted on 60 medical students in Thailand. They found 500 mg/day orally administered GSH, for 4 weeks to cause significant skin whitening when compared to placebo and they observed no significant adverse events. However, there were many flaws in the study-plasma GSH levels were not measured (as bioavailability of oral GSH is low), limited study period of 4 weeks, no follow-up to determine when the skin melanin indices return to their baseline values, medical students were chosen (young, otherwise healthy population) and the study was conducted during their college time to ensure that sun exposures were minimal. Hence, the results may be applicable to only young, otherwise healthy Asian individuals.

The promoters of GSH promote it at a dose of 20 and 40 mg/kg/body weight/day which is divided into two doses with a maintenance dose of 500 mg/day. [7] They claim that gradual systemic effect will be seen 1-3 months in medium brown skin, in 3-6 months in dark brown skin, in 6-12 months in very dark skin and in 2 years are more in black skin. Injectable GSH is given at a dose of 900 mg weekly by intravenous or intramuscular method and the sessions can be repeated 2-3 times a week. They claim skin whitening to occur as early as 2-3 weeks. [7]

GSH is also combined with many other agents like vitamin C to increase its absorption, N-acetyl cysteine to boost its level, alpha lipoic acid and other antioxidants like vitamin E and grape seed extract. Some oral preparations have dangerous combinations like monobenzone which causes irreversible depigmentation and hydroquinone which is banned by FDA as a carcinogen. [8]

L-cysteine peptide

Another agent promoted for skin whitening is L-cysteine peptide, which is claimed to be 3-5 times more potent than GSH and is BFAD approved. [9] Natural sources of L-cysteine include poultry, yogurt, egg yolks, red peppers, garlic, onions, broccoli, Brussel sprouts, oats, and wheat germ. L-cysteine along with L-glutamic acid and glycine is the rate-limiting precursor in the synthesis of GSH peroxidase and has been found that high concentrations of L-cysteine reduced the tyrosinase activity and produced more pheomelanin by way of cysteinyl dihydroxyphenylalanine (DOPA), the building block of pheomelanin [Figure - 1]. The cysteinyl DOPAs can be formed in two ways-directly by nucleophilic addition of cysteine to DOPA quinone or indirectly from GSH DOPA by action of gamma-glutamyl transferase and peptidase. [10],[11],[12] Hence L-cysteine peptide is promoted as skin whitening agent but without much scientific evidence to support its use for this indication.

Tranexemic acid

Tranexemic acid (trans-4-aminomethyl cyclohexane carboxylic acid), a plasmin inhibitor, commonly used as a haemostatic agent owing to its antifibrolytic action is also promoted as a systemic skin whitening agent especially as oral or intradermal injections for melasma. The skin whitening effects of tranexamic acid was incidentally found when it was used in the treatment of aneurysmal subarachnoid hemorrhage. It is a synthetic derivative of lysine and its therapeutic role in melasma was first studied by Nijor as early as in 1979, but only limited data exist in the literature regarding its use in melasma. Plasmin, is a protease that enhances the intracellular release of arachidonic acid, a precursor of prostanoid, and also elevates alpha-melanocyte stimulating hormone (α-MSH) processed from pro-opio-melanocortin. Both arachidonic acid and α-MSH can activate melanin synthesis by melanocytes. Tranexemic acid by way of its antiplasmin activity depletes the keratinocyte pool of arachidonic acid involved in ultraviolet (UV) induced melanogenesis. [13],[14],[15],[16],[17]

It has been used at a low dose of 250 mg twice a day for at least 3 months for the treatment of melasma and found to be effective. [15] But, it is not safe to use it for a long duration in view of its anti-hemorrhagic property resulting in side effects like venous thromboembolism, myocardial infarction, cerebrovascular accidents and pulmonary embolism. It is contraindicated in patients with acquired defective color vision, an active intravascular clotting condition, and hypersensitivity to tranexemic acid. [15] However, there is no scientific data available demonstrating the role of tranexemic acid as an overall skin whitening/lightening agent. It is even being promoted as intravenous injection for skin whitening at a dose of 500 mg every week for 1 or 2 months and 500 mg every month for maintenance. [18] Tranexamic acid has been found to produce good synergistic effect when combined with ascorbic acid or its derivatives and L-cysteine. [17]

Miscellaneous agents

Apart from these, large doses of vitamin C, hyaluronic acid, epidermal growth factor and combinations of multiple natural extracts (natural collagen extracts, bearberry extract, Glycyrrhiza glabra extract, Lycopene, Kelp, olive leaf extract, hawthorn, jujube, sea buckthorn, starch, coix seed, pearl extracts, etc.,) are also promoted for skin whitening in the form of food or dietary supplements with no scientific evidence.

Nevertheless, there are few animal studies and in vitro studies demonstrating the role of natural extracts like irradiated green tea polyphenol, [19] proanthocyanidin-rich extract from grape seeds, [20] ellagic acid-rich pomegranate extract, [21] and coumarin extracts from the plant Angelica dahurica, [22] in inhibiting melanogenesis resulting in skin whitening thereby recommending these agents as oral preparations for skin whitening. Procyanidins (pycnogenol, grape seed extracts) and Polypodium leucotomos have been found to effective and safe in the treatment of melasma and to prevent UV A induced pigmentary changes respectively. [23] But there are no trials demonstrating their efficacy in the treatment of post inflammatory pigmentation or in improving the general skin color.

The Scenario in India

In India, GSH is available as Dr. James GSH whitening pills [24] which contains 100% natural pure GSH with alpha T-acids costing 3500/- rupees for 60 capsules of 1000 mg, I-Fair tablets [25] which contains GSH in combination with vitamin C, vitamin E, grape seed extract, alpha lipoic acid, and glutanova 900 skin whitening injections [10] which contains GSH with vitamin C and collagen. These agents are being advertised in the internet and currently there are no market data available on the use of these agents by Indians. As mentioned in the introduction, most of Indian women′s marriage prospects are dominated by skin color paving way for irrational use of these agents by these women and may result in untoward effects. Hence, well conducted studies, establishing the role of these agents in skin whitening and documenting adverse events is the need of the hour.

Problems with Systemic Skin Whitening Agents

As already mentioned above, these agents are not FDA approved for skin whitening and no scientific evidence exists for their use. In addition, the injectable formulations are counterfeited and given by untrained people illegally and hence associated with the risk of sepsis, air embolism, transmission of human immunodeficiency virus, Hepatitis B, and use of non-sterile preparations that can lead to serious infections.

Another major question that remains unanswered as yet is that whether switching the normal machinery from eumelanin (which is protective against UV radiation) to pheomelanin (which photosensitizes UV-induced deoxyribonucleic acid damage as observed in cultured human melanocytes) by an external agent for long duration would result in an increased incidence of skin cancers. [26],[27]

As a general rule, the promoters of the systemic skin whitening agents list lactation, heart disease and hypersensitivity as contraindications for all these agents. Since there are not much human or animal studies advocating the role of these agents in skin whitening, there is no data on the relative and absolute contraindications, the appropriate dosing schedule and the long term side effects.

Economic Considerations

In India, the dermatology market is worth 1642 crore rupees ($410 million) and fairness-directed skin lightening cosmetic market (which are considered as ′′fast moving consumer goods′′) is 1000 crore ($ 250 million) resulting in a staggering 61% of the total dermatology market. [28] Companies manufacturing skin lightening products take advantage of the lax advertising laws and make unsubstantiated claims about their efficacy taking a horrendous toll on the consumers. The high-end skin whitening products are often labeled under the new quasi-pharmaceutical category called cosmeceuticals - a hybrid entity with pharmaceutical and cosmetic properties. This ambiguous labeling strategy allows promoters of high-end skin whitening and anti-aging products to make both pharmaceutical and cosmetic claims. The marketing trends are designed in such a way so as to blur the lines between cosmetics and food categories and food and pharmaceutical categories, thereby helping in evading the regulatory constraints for these products, eventually enticing more consumers to consume these relatively expensive and poorly regulated products. Thus, their claims can neither be independently verified, nor can potential risks to consumers be assessed. [29]

Conclusion

The desire for white and fair skin is a global phenomenon and it is being highly capitalized by both the cosmetic and dermatologic industries. It is an essential role of the dermatologist to make the public aware that skin lightening agents may progressively revert back the facultative color to the constitutive level and normally this color change will not go beyond the constitutive level. If such a change is claimed, it should be considered to be dangerous as such alterations can become non-reversible resulting in vitiligo and may also predispose to other complications like skin cancer as the normal biochemical processes are altered. Till date, systemic skin whitening agents do not have much scientific evidence regarding their use and strict laws should be enforced to ban the use of these agents until well conducted randomized controlled trials are available ensuring the safety and efficacy of these agents.

References